版本:
中国

BRIEF-Parvus Therapeutics announces license and collaboration agreement of its lead nanomedicine to treat type 1 diabetes

April 19 Novartis Ag

* Parvus therapeutics announces exclusive worldwide license and collaboration agreement for development and commercialization of its lead nanomedicine to treat type 1 diabetes

* Parvus therapeutics says has entered into a license and collaboration agreement with novartis for its lead navacim for treating type 1 diabetes

* Parvus-Under terms,novartis receives exclusive, worldwide rights to use parvus' navacim technology to develop, commercialize products for treatment of type 1 diabetes

* Parvus therapeutics - novartis will be responsible for clinical-stage development and commercialization activities

* Parvus therapeutics says novartis has also made an equity investment in parvus

* Parvus therapeutics - parvus has received an upfront payment and will receive research funding to support preclinical activities Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐